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NUCLEIC ACIDS ENCODING SARC 0C YST IS 
NE URONA ANTIGEN AND USES THEREOF 
The present application is a continuation of US. utility 
patent application Ser. No. 11/445,045, ?led on Jun. 1, 2006 
now US. Pat. No. 7,256,282, Which in turn claims priority to 
US. utility patent application Ser. No. 10/369,430, ?led on 
Feb. 19, 2003, Which claims the bene?t of priority of US. 
provisional patent application No. 60/357,479, ?led Feb. 15, 
2002, the disclosures of each of Which are incorporated herein 
in their entirety by reference. 
TECHNICAL FIELD 
The present invention relates to nucleic acids of Sarcocys 
Zis neurona. In particular, the present invention relates to 
nucleic acids of Sarcocyslis neurona and to nucleic acid 
reagents and antibodies for use in methods of detection and 
prevention of Sarcocyslis neurona infection. More particu 
larly, the present invention relates to novel nucleic acid 
sequences of Sarcocyslis neurona and to utiliZation thereof 
including primers, probes, antigen/antibody diagnostic kits, 
vectors for production of peptides encoding the novel nucleic 
acids, and to antigenic proteins and vaccines against Sarco 
cyslis neurona. 
BACKGROUND OF THE INVENTION 
Sarcocyslis neurona is an apicomplexan parasite that is the 
primary cause of equine protoZoal myeloencephalitis (EPM; 
Dubey et al., 1991), Which is a common and debilitating 
infectious disease that affects the central nervous system of 
horses. S. neurona is related to the human and animal patho 
gen Toxoplasma gondii and to the important veterinary patho 
gen Neospora spp. The geographic range of S. neurona 
appears to be limited to the Western hemisphere, thus EPM 
primarily affects horses in the Americas. 
De?nitive antemortem diagnosis of EPM remains exceed 
ingly dif?cult, for a variety of reasons. Horses af?icted With 
EPM exhibit signs that are similar to a number of different 
neurological disorders (MacKay et al., 2000). Furthermore, 
S. neurona infection does not equate to disease, since only a 
small proportion of seropositive horses Will suffer from EPM 
(MacKay et al., 2000); as a consequence, the detection of 
anti-S. neurona antibodies in serum provides little diagnostic 
information other than indicating previous exposure to the 
parasite. Analysis of cerebrospinal ?uid (CSF) to reveal 
intrathecal antibody production has improved the predictive 
value of antibody detection for EPM diagnosis. HoWever, 
interpretation of CSF antibody presence can be confounded 
by contamination of the CSF sample With minute amounts of 
serum antibodies (Miller et al., 1999). 
Other contemporary diagnostic assays provide only 
mediocre predictive value for EPM diagnosis. Western blot 
analysis (a.k.a., immunoblot) of crude S. neurona lysate 
remains the principal immunodiagnostic test that is used to 
detect antibodies in suspect EPM horses (Granstrom et al., 
1993). The assay relies on the recognition of several antigens, 
primarily in the loW molecular Weight range, by serum/CSF 
antibodies (Dubey et al., 2001b; Granstrom et al., 1993; 
MacKay et al., 2000). Unfortunately, Western blot analysis is 
primarily a research tool that is relatively laborious and some 
What hindered by subjectivity, so any improvements to the 
immunoblot are of limited value. While the immunoblot has 
been utiliZed for a number of years to help diagnose EPM, it 
is a ?rst-generation test that needs to be replaced With 
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Improved assays based on simpli?ed, and thus more reliable, 
techniques that are more appropriate for diagnostic use. 
Nucleic acid ampli?cation assays (polymerase chain reac 
tion; PCR) for S. neurona detection have been developed 
based on the S. neurona ribosomal RNA genes (Fenger et al., 
1994; Marsh et al., 1996). These PCR-based assays detect the 
presence of S. neurona DNA, and therefore the parasite, in the 
horse, so they can provide a de?nitive indication of active 
infection. HoWever, prior to the present invention, these 
nucleic acid-based tests have been inherently unreliable. Spe 
ci?cally, parasites may be very feW or non-existent in a CSF 
sample, so there Will be feW or no available target molecules 
(i.e., parasite genomic DNA) for PCR ampli?cation. More 
importantly, the general use of PCR for diagnosis is still 
suspect. Although measures can be taken to improve the 
reliability of PCR, the technique continues to be troubled by 
both false positive and false negative results. 
The selection of an antigen for development of a diagnostic 
test can be someWhat subjective since any particularpathogen 
is composed of numerous antigenic proteins. Logically, the 
target molecule in a diagnostic assay must elicit a detectable 
antibody response in the infected animal. In this regard, sur 
face antigens of the Coccidia, such as the primary surface 
antigens of Toxoplasma gondii (Handman and Remington, 
1980; Sharma et al., 11983) and Neospora caninum (HoWe et 
al., 1998), are exceedingly immunogenic. These surface anti 
gens have been designated SAGs and SAG-related sequences 
(SRSs). Signi?cantly, the TgSAGl surface antigen of T gon 
dii has been shoWn to protect mice against acute toxoplasmo 
sis (BuloW and Boothroyd, 1991), and the NcSAGl (p29) 
major surface antigen of N. caninum has been used to develop 
an ELISA for detection of Neospora infection in cattle (Howe 
et al., 2002). Collectively, these previous studies demonstrate 
that coccidian SAGs are at least candidate proteins for the 
development of both diagnostic assays and protective vac 
cines. 
Despite the foregoing art, prior to the present invention it 
had not been shoWn that the surface antigens of S. neurona 
(i.e., SnSAG2, SnSAG3, and SnSAG4) are effective target 
molecules for examining immune responses in infected 
horses and for developing improved assays for EPM diagno 
sis. Such molecules Would also provide the basis for 
improved vaccines and diagnostic kits, including antigen and 
antibody kits, for fast and reliable diagnosis of S. neurona 
infection. 
SUMMARY OF THE INVENTION 
The present invention satis?es the aforementioned need in 
the art by providing a novel isolated nucleic acid encoding an 
antigenic protein derived from Sarcocyslis neurona, or a 
unique fragment thereof. In one embodiment, the invention 
provides novel isolated nucleic acids encoding membrane 
associated polypeptides SnSAG2, SnSAG3, and SnSAG 4. 
The present invention also provides puri?ed antigenic 
polypeptide fragments encoded by the novel nucleic acid 
sequences set forth herein that encode for Sarcocyslis neu 
rona. In one embodiment, the invention provides puri?ed 
antigenic proteins or puri?ed antigenic polypeptide frag 
ments encoded by the novel nucleic acid sequences set forth 
herein that encode for SnSAG2, SnSAG3, and SnSAG4. In 
another embodiment, the present invention provides a puri 
?ed antigenic polypeptide fragment encoded by the nucleic 
acid sequences set forth herein or a selective portion thereof 
in a pharmaceutically acceptable carrier. 
The present invention also provides isolated nucleic acids 
capable of selectively hybridizing With the nucleic acid from 
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Sarcocyslis neurona including, but not limited to, primers and 
probes for utilization in polymerase chain reaction (PCR) and 
other nucleic acid ampli?cation techniques. The isolated 
nucleic acids of the present invention are capable of hybrid 
iZing under conditions of loW, moderate, and high stringency 
With a nucleic acid from Sarcocyslis neurona. 
Further, the present invention provides vectors comprising 
the isolated nucleic acids, or degenerate variants thereof, set 
forth herein encoding Sarcocyslis neurona or a unique frag 
ment thereof and provides the vector in a host capable of 
expressing the polypeptide encoded by that nucleic acid. 
Still yet further, the present invention also provides a puri 
?ed polyclonal and or a monoclonal antibody speci?cally 
reactive With Sarcocyslis neurona and a method of detection 
of Sarcocyslis neurona utiliZing the antibodies of the present 
invention. 
The above-described embodiments provided by the 
present invention, provide a method for detecting Sarcocyslis 
neurona in a biological sample, comprising detecting the 
presence in the sample of an antibody or fragment thereof 
Which speci?cally binds to a polypeptide comprising an iso 
lated amino acid sequence selected from the group set forth in 
the Sequence Listing as SEQ ID NO.: 24, SEQ ID NO: 26, 
and SEQ ID NO: 28. In one embodiment of the method, the 
biological sample is serum. In another embodiment, the 
present invention provides a method as described for detect 
ing Sarcocyslis neurona in cerebrospinal ?uid (CSF). 
Finally, the present invention provides a kit for detecting 
Sarcocyslis neurona in a biological sample, comprising at 
least one isolated amino acid sequence selected from the 
group set forth in the Sequence Listing as SEQ ID NO.: 24, 
SEQ ID NO: 26, and SEQ ID NO: 28, and a reporter molecule 
for detecting a ?rst antibody or fragment thereof Which spe 
ci?cally binds to a polypeptide comprising the at least one 
isolated amino acid sequence. The reporter molecule may be 
any suitable detectable second antibody or fragment thereof 
Which binds to the ?rst antibody or fragment thereof, and 
Which is labeled With a detectable moiety or bound to a 
substrate. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a sequence comparison of mature SnSAG1 (SEQ 
ID NO.:31), SnSAG4 (SEQ ID NO: 32), and SnSAG3 (SEQ 
ID NO.: 33) With SmMSA (SEQ ID NO.: 34) and TgSAG2E 
(SEQ ID NO.:35). The S. neurona surface antigens SnSAG1, 
SnSAG3 and SnSAG4 are most similar to the TgSAG2 family 
of T gondi surface antigens. The sequences presented in the 
Figure are for the mature proteins after cleaving off the N-ter 
minal signal peptide and the C-terminal signal for the GPI 
anchor. Sequence alignments of the predicted mature proteins 
revealed very moderate sequence identity (<25%). HoWever, 
the SnSAGs contain 10/12 conserved cysteine residues that 
have been observed previously, suggesting that the SnSAGs 
have a tertiary structure that is similar to What has been 
determined for the TgSAGs/SRSs. 
FIG. 2 is a sequence comparison of mature SnSAG2 (SEQ 
ID NO.: 36) With TgSAG1 (SEQ ID NO.: 37) and TgSRS2 
(SEQ ID NO.: 38). The sequences presented in the Figure are 
for the mature proteins after cleaving off the N-terminal sig 
nal peptide and the C-terminal signal for the GPI anchor. The 
S. neurona surface antigen SnSAG2 is most similar to the 
TgSAG1 family of T gondii surface antigens. Similar to the 
other SnSAGs, SnSAG2 shares modest sequence identity to 
its TgSAG orthologues, but contains 6/6 conserved cysteine 
residues that have been observed in each half of the proto 
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typical tWo-domain apicomplexan SAG. SnSAG2 Will also 
align With the carboxyl-terminal domain of the TgSAGs. 
FIG. 3 shoWs a Western blot analysis of the SnSAGs in S. 
neurona meroZoites. The SnSAG genes Were expressed in E. 
coli, and monospeci?c polyclonal antisera Were generated 
against the recombinant proteins. Western blot analysis of 
reduced antigen revealed that each SnSAG migrated signi? 
cantly higher than its predicted molecular Weight, consistent 
With What has been observed for the T gondii SAGs/SRS. 
SnSAG1 and SnSAG4 co-migrated and corresponded to the 
immunodominant band at about 30-32 kDa. SnSAG2 corre 
sponded to an immunodominant band at approximately 18-20 
kDa. 
FIG. 4 shoWs the SnSAGs are membrane-associated in 
Sarcocyslis neurona meroZites. Triton X-114 partitioning 
assays indicated that the SnSAGs are associated With mem 
branes, consistent With their surface localiZation via gly 
colipid anchoring. Western blot analysis of the partitioned 
proteins With the SnSAG-speci?c polyclonal antisera 
revealed that all four SnSAGs Were separated exclusively into 
the detergent phase (D). The control protein, SnMIClO, Was 
partitioned into the aqueous phase (A), as expected. 
FIG. 5 shoWs that the four SnSAGs are displayed on the 
surface of Sarcocyslis neurona meroZoites. Surface biotiny 
lation of S. neurona meroZoites indicated that the four 
SnSAGs are displayed on the surface of the parasite. Western 
blot analysis With the SnSAG-speci?c antisera revealed each 
of the SnSAGs in the biotinylated protein fraction precipi 
tated With immobiliZed streptavidin. The SnSAGs Were not 
present in the non-labeled parasites, thus indicating that the 
streptavidin precipitation Were speci?c for biotin-labeled 
proteins. The negative control protein (actin) Was not detected 
in the biotin-labeled/streptavidin-precipitated protein frac 
tion. 
FIG. 6 shoWs reciprocal antibody titers in serum of EPM 
con?rmed horses, determined by an ELISA using the recom 
binant surface antigens of the present invention. 
FIG. 7 shoWs reciprocal antibody titers in CSF of EPM 
con?rmed horses, determined by an ELISA using the recom 
binant surface antigens of the present invention. 
FIG. 8 shoWs expression of S. neurona surface antigens in 
COS-1 (green monkey kidney) cells, detected by immunof 
luorescent labeling With ?uorescein isothiocyanate. 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention may be understood more readily by 
reference to the folloWing detailed description of speci?c 
embodiments and the examples included therein. As used in 
the claims, “a” can mean one or more. As can be appreciated 
by one of skill in the art, methods and materials similar or 
equivalent to those described herein can be used in the prac 
tice of the present invention. All publications, patent applica 
tions, patents, and other references mentioned herein are 
incorporated by reference in their entirety in order to more 
fully describe the state of the art to Which this invention 
pertains. It is noted that the abbreviated citations of literature 
referenced herein are set forth fully in US. patent application 
Ser. No. 10/369,430, the disclosure ofWhich is also incorpo 
rated herein in its entirety by reference. 
Although the present invention has been described With 
reference to speci?c details of certain embodiments thereof, it 
is not intended that such details should be regarded as limi 
tations upon the scope of the invention except as and to the 
extent that they are included in the accompanying claims. In 
the case of a con?ict With incorporated references, the present 
speci?cation, including de?nitions, Will control. In addition, 
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the particular embodiments discussed below are illustrative 
only and not intended to be limiting. 
The present invention satis?es the long felt need in the art 
by providing novel isolated nucleic acid sequences Which 
encode antigenic proteins derived from Sarcocyslis neurona, 
or Which encode unique antigenic protein fragments thereof. 
As used herein, a “nucleic acid” means a chain of at least tWo 
or more nucleotides such as DNA (deoxyribonucleic acid) or 
RNA (ribonucleic acid). As used herein, a “puri?ed” nucleic 
acid is one that is substantially separated from other nucleic 
acid sequences in a cell or organism in Which the nucleic acid 
naturally occurs. Likewise, by “isolated” nucleic acid is 
meant separated from at least some of other nucleic acids 
found in the naturally-occurring organism. The nucleic acids 
of the present invention can include positive and negative 
strand RNA as Well as DNA. The above terms encompass 
double-stranded DNA, single-stranded DNA, and RNA and 
are meant to include genomic and subgenomic nucleic acids 
found in the naturally-occurring Sarcocyslis neurona organ 
ism. The nucleic acids contemplated by the present invention 
include a nucleic acid having sequences from Which a Sarco 
cyslis neurona cDNA can be transcribed; or allelic variants 
and/or homologs of thereof. By “capable of selectively 
hybridizing” is meant a sequence Which does not hybridize 
With other nucleic acids to prevent an adequate positive 
hybridization With nucleic acids from Sarcocyslis neurona 
and is meant to include stringent hybridization conditions 
including loW, moderate and high stringency conditions. Such 
stringency conditions are knoWn in the art, e.g., in US Patent 
Publication No.: 2002/01 15828 A1. By “unique fragment” is 
meant a fragment of the nucleic acids set forth in the 
Sequence Listing that is less than the full length that can 
selectively hybridize With a RNA, DNA or cDNA sequence 
derived from the novel sequences set forth herein or that can 
selectively hybridize With nucleic acids from Sarcocyslis 
neurona. Modi?cations to the nucleic acids of the invention 
are also contemplated as long as the essential structure and 
function of the polypeptide encoded by the nucleic acids is 
maintained. Likewise, fragments used as primers or probes 
can have substitutions so long as enough complementary 
bases exist for selective hybridization (Kunkel et al. Methods 
Enzmol. 1987: 154-367, 1987). As one of skill in the art can 
appreciate, there can be naturally occurring allelic variants 
and non-naturally occurring variants or modi?cations of the 
nucleic acids of the invention. For example, homologs or 
naturally occurring allelic variants of the nucleic acids of the 
invention having from about 50% and up to about 99% 
sequence identity are contemplated by the invention. Like 
Wise, it is contemplated that non-naturally occurring variants 
or modi?cations of the nucleic acids of the invention can 
range from about 50% to about 99% sequence identity to 
native S. neurona are contemplated. 
In particular, one embodiment of the present invention 
provides isolated nucleic acids derived from three Sarcocyslis 
neurona cluster sequences, namely Sn Cluster 144, Sn Clus 
ter 21 and Sn Cluster 4, Which comprise the nucleotide 
sequences set forth in the Sequence Listing as SEQ ID NOS: 
1, 3, and 29 respectively and the sequences complimentary 
thereto. Also provided by the invention are the corresponding 
protein or polypeptide amino acid sequences for these three 
Sarcocyslis neurona cluster sequences. The polypeptide 
sequence comprising Sn Cluster 144 is set forth in the 
Sequence Listing as SEQ ID NO: 2. The polypeptide 
sequence comprising Sn Cluster 21 is set forth in the 
Sequence Listing as SEQ ID NO: 4 and the polypeptide 
sequence comprising Sn Cluster 4 is set forth in the Sequence 
Listing as SEQ ID NO: 30. As used herein, the terms 
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“polypeptide” and “protein” are used interchangeably and are 
meant to include any peptide-linked chain of amino acids, 
regardless of length or post-translational modi?cation, e.g., 
glycosylation or phosphorylation. By “puri?ed” polypeptide 
is meant a polypeptide that has been substantially separated 
or isolated aWay from other polypeptides in a cell, organism, 
or mixture in Which the polypeptide occurs. 
Similar to other members of the Apicomplexa, S. neurona 
is an obligate intracellular pathogen that utilizes a number of 
unique structures and molecules (i.e., virulence factors) to 
support its parasitic lifestyle. Parasite surface molecules are 
virulence factors that are typically novel and undoubtedly 
important since they are responsible for the initial interac 
tions With the host cell surface and host immune response. In 
Toxoplasma gondii, for example, an extensive family of 25+ 
surface antigens has been identi?ed, Which are developmen 
tally regulated and exhibit various levels of sequence similar 
ity to either of the major T gondii surface antigens TgSAGl 
or TgSAG2. These surface molecules appear to be involved in 
receptor/ligand interactions With the host cell surface, and 
there is increasing evidence that some of the T gondii SAGs 
are involved in modulation of host immune responses. 
In one embodiment, the present invention provides identity 
and characterization of certain of the virulence factors of S. 
neurona. In particular, the present invention provides four 
isolated nucleic acids of S. neurona (genes) that encode para 
sitic surface antigens. A sequencing project Was conducted 
that generated approximately 8500 expressed sequence tags 
(ESTs) from this organism. Examination of this sequence 
database has revealed a family of at least four S. neurona 
surface antigens that are orthologues of the SAG/SRS family 
of surface proteins in T gondii. Each protein is predicted to 
contain an amino-terminal signal peptide and a carboxyl 
terminal glycolipid anchor addition site, indicating surface 
localization, and Triton X-l 14 partitioning and surface bioti 
nylation assays con?rmed that all four proteins are mem 
brane-associated and displayed on the S. neurona merozoite 
surface (See, FIGS. 4 and 5). Additionally, these novel S. 
neurona proteins possess multiple conserved cysteine resi 
dues that have been described previously for T gondii SAGs 
and Which are likely important for the tertiary structure of the 
proteins (See, FIGS. 1 and 2). Due to their surface localiza 
tion and relative homology to T gondii surface antigens, these 
S. neurona proteins have been designated SnSAGl, SnSAG2, 
SnSAG3, and SnSAG4. 
Accordingly, one embodiment of the present invention 
comprises an isolated nucleic acid as set forth in the Sequence 
listing as SEQ ID NO: 21. The nucleic acid identi?ed in SEQ 
ID NO: 21 comprises an 828-nucleotide open reading frame 
of the SnSAG1 gene of Sarcocyslis neurona Which encodes a 
276 amino acid polypeptide set forth in the Sequence Listing 
as SEQ ID NO: 22. The polypeptide encoded by SEQ ID NO: 
22 has a predicted amino-terminal signal peptide (indicating 
expression via the secretory pathWay) and a glycolipid anchor 
addition site at the carboxy-terminal end (indicating surface 
localization). Database searches With the predicted protein 
sequence of SnSAG1 (rSnSAGl) revealed signi?cant simi 
larity (alignment score:80, E value:2><10—14) to a 31 kDa 
surface antigen from Sarcocyslis muris. 
A recombinant form of the Sarcocyslis neurona SnSAG1 
(rSnSAGl) has been expressed in E. coli. Western blot analy 
sis of rSnSAGl demonstrated that the recombinant antigen is 
recognized by antiserum from a rabbit that Was immunized 
With S. neurona merozoites and by antibodies in cerebrospi 
nal ?uid (CSF) from an EPM (Sarcocyslis neurona infected) 
horse (See, e.g., FIG. 3). 
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Another embodiment of the present invention comprises an 
isolated nucleic acid as set forth in the Sequence listing as 
SEQ ID NO: 23. The nucleic acid identi?ed in SEQ ID NO: 
23 comprises an 975 nucleotide open reading frame of the 
SnSAG2 gene of Sarcocyslis neurona Which encodes a 168 
amino acid polypeptide set forth in the Sequence Listing as 
SEQ ID NO: 24. 
The present invention also provides an isolated nucleic 
acid as set forth in the Sequence listing as SEQ ID NO: 25. 
The nucleic acid identi?ed in SEQ ID NO: 25 comprises an 
1585 nucleotide open reading frame of the SnSAG3 gene of 
Sarcocyslis neurona Which encodes a 281 amino acid 
polypeptide set forth in the Sequence Listing as SEQ ID NO: 
26. 
Also provided by the present invention is an isolated 
nucleic acid as set forth in the Sequence listing as SEQ ID 
NO: 27. The nucleic acid identi?ed in SEQ ID NO: 27 com 
prises an 1 l l l nucleotide open reading frame of the SnSAG4 
gene of Sarcocyslis neurona Which encodes a 287 amino acid 
polypeptide set forth in the Sequence Listing as SEQ ID NO: 
28. 
As set forth more fully beloW, these genes have been 
expressed as recombinant proteins in E. coli. The recombi 
nant SnSAG proteins can be implemented into antibody 
capture ELISAs and used to detect the presence of S. neurona 
antibodies in a sample. Likewise, the recombinant proteins 
provided by the invention can be used as reagents for use in 
vaccines against S. neurona. 
Another embodiment of the present invention includes the 
discovery of additional novel expressed sequence tags (EST) 
that encode novel antigenic peptides for utiliZation in the 
vaccines and diagnostic kits as disclosed by this invention. 
In particular, cluster analysis of the Sarcocyslis neurona 
expressed sequence tags (ESTs) generated from the cSn.l 
cDNA library has revealed a gene family that encodes at least 
eight homologous proteins. Of the approximately 8500 S. 
neurona ESTs that have been generated thus far, roughly 540 
sequences can be placed in this gene family, Which has been 
provisionally designated SnGFl (S. neurona Gene Family 1). 
Based on its relative abundance in the collection of S. neurona 
ESTs, SnGFl encodes a set of similar proteins (at least eight) 
that are highly expressed and most likely play signi?cant 
roles in the biology of S. neurona (i.e., parasite virulence 
factors). In addition to their biological importance, the abun 
dance of these proteins Would suggest that they elicit signi? 
cant immune responses in infected animals. Collectively, the 
characteristics of the novel nucleic acids of SnGFl, and the 
encoded proteins therefrom, make this gene family Well 
suited for the development of improved diagnostics and/or 
vaccines for EPM as set forth herein. 
The eight SnGFl isoforms identi?ed thus far have been 
designated SnGFla-h. These genes are predicted to encode 
proteins of, e.g., 109 amino acids, 106 amino acids, and 107 
amino acids in length, and the proteins share approximately 
70% to 80% sequence identity. These proteins have a pre 
dicted N-terminal signal peptide and a predicted transmem 
brane domain near the C-terminus. The SnGFl members 
shoW no similarity to sequences in the current public gene 
databases, suggesting that SnGFl is relatively unique to S. 
neurona. 
Accordingly, one embodiment of the present invention 
provides an isolated nucleic acid designated SnGFla Which 
comprises the nucleic acid set fort in SEQ ID NO: 5 and 
sequences complimentary thereto. Another embodiment of 
the invention comprises the polypeptide sequence encoded by 
SnGFla set forth in the Sequence Listing as SEQ ID NO: 6. 
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Another embodiment of the present invention provides an 
isolated nucleic acid designated SnGFlb Which comprises 
the nucleic acid set forth in SEQ ID NO: 7 and sequences 
complimentary thereto. Another embodiment of the invention 
comprises the polypeptide sequence encoded by SnGFlb set 
forth in the Sequence Listing as SEQ ID NO: 8. 
Yet another embodiment of the present invention provides 
an isolated nucleic acid designated SnGFlc Which comprises 
the nucleic acid set forth in SEQ ID NO: 9 and sequences 
complimentary thereto. Another embodiment of the invention 
comprises the polypeptide sequence encoded by SnGFlc set 
forth in the Sequence Listing as SEQ ID NO: 10. 
Still another embodiment of the present invention provides 
an isolated nucleic acid designated SnGF l d Which comprises 
the nucleic acid set forth in SEQ ID NO: 11 and sequences 
complimentary thereto. Another embodiment of the invention 
comprises the polypeptide sequence encoded by SnGFld set 
fort in the Sequence Listing as SEQ ID NO: 12. 
The present invention also provides an isolated nucleic 
acid designated SnGFle Which comprises the nucleic acid set 
fort in SEQ ID NO: 13 and sequences complimentary thereto. 
Another embodiment of the invention comprises the polypep 
tide sequence encoded by SnGFle set forth in the Sequence 
Listing as SEQ ID NO: 14. 
Another embodiment of the present invention provides an 
isolated nucleic acid designated SnGF l f Which comprises the 
nucleic acid set forth in SEQ ID NO: 15 and sequences 
complimentary thereto. Another embodiment of the invention 
comprises the polypeptide sequence encoded by SnGFlf set 
forth in the Sequence Listing as SEQ ID NO: 16. 
Yet another embodiment of the present invention provides 
an isolated nucleic acid designated SnGF l g Which comprises 
the nucleic acid set forth in SEQ ID NO: 17 and sequences 
complimentary thereto. Another embodiment of the invention 
comprises the polypeptide sequence encoded by SnGFlg set 
forth in the Sequence Listing as SEQ ID NO: 18. 
Still another embodiment of the present invention provides 
an isolated nucleic acid designated SnGFlh Which comprises 
the nucleic acid set forth in SEQ ID NO: 19 and sequences 
complimentary thereto. Another embodiment of the invention 
comprises the polypeptide sequence encoded by SnGFlh set 
forth in the Sequence Listing as SEQ ID NO: 20. 
The present invention provides isolated nucleic acids as set 
forth in the Sequence Listing and nucleic acid reagents 
derived therefrom Which can be utiliZed to diagnose and 
prevent infection of S. neurona. Puri?ed polypeptides 
encoded by the nucleic acids are also provided. These 
polypeptides can be utiliZed in methods of diagnosis or as 
vaccine components for prevention of infection. Vectors are 
also provided Which comprise the nucleic acids of the present 
invention. The vectors can be utiliZed in host expression 
systems to produce antigenic peptide reagents for diagnostic 
and prophylactic applications. The present invention also pro 
vides puri?ed antibodies selectively reactive With S. neurona. 
These antibodies can be used in various diagnostic methods 
or as a therapeutic. 
In one embodiment, the invention provides puri?ed anti 
genic polypeptides encoded by the nucleic acids set forth in 
the Sequence Listing. The invention also provides these anti 
genic polypeptides in a pharmaceutically acceptable carrier. 
The amino acid sequence of these polypeptides can be 
deduced from the nucleotide sequences set forth in the 
Sequence Listing. 
Puri?ed antigenic polypeptide fragments encoded by the 
nucleic acids of the present invention are also contemplated. 
As used herein, “puri?ed” means the antigen is at least su?i 
ciently free of contaminants or cell components With Which 
US 7,524,946 B2 
the antigen normally occurs to distinguish the antigen from 
the contaminants or components. Puri?ed antigenic polypep 
tides of S. neurona and antigenic fragments thereof of the 
present invention are also referred to herein as “the antigen” 
or “the S. neurona antigen.” It is contemplated that the anti 
genic fragments can be encoded from any portion of the 
nucleic acid encoding S. neurona as set forth in the Sequence 
Listing, but especially from fragments encoded by the open 
reading frames set forth in SEQ ID NOS: 24, 26 and 28 as 
described herein. Speci?cally, one example provides an 
approximately 12 kDa antigenic polypeptide encoded by an 
open reading frame of SEQ ID NO: 24 consisting essentially 
of the amino acids encoded by the nucleotide as sequence set 
forth in the Sequence Listing as SEQ ID NO: 23. 
An antigenic fragment of the antigen can be isolated from 
the Whole antigen by chemical or mechanical disruption. The 
puri?ed fragments thus obtained can be tested to determine 
their antigenicity and speci?city by the methods taught 
herein. Antigenic fragments of the antigen can also be syn 
thesiZed directly. An immunoreactive fragment is generally 
an amino acid sequence of at least about ?ve consecutive 
amino acids derived from the antigen amino acid sequence. 
The polypeptide fragments of the present invention can 
also be recombinant proteins obtained by cloning nucleic 
acids encoding the polypeptide in an expression system 
capable of producing the antigenic polypeptide or fragments 
thereof. 
Once the amino acid sequence of the antigen is provided, it 
is also possible to synthesiZe, using standard peptide synthe 
sis techniques, peptide fragments chosen to be homologous to 
immunoreactive regions of the antigen and to modify these 
fragments by inclusion, deletion or modi?cation of particular 
amino acids residues in the derived sequences. Thus, synthe 
sis or puri?cation of an extremely large number of peptides 
derived from the antigen is possible. 
The amino acid sequences of the present polypeptides can 
contain an immunoreactive portion of the S. neurona antigen 
attached to sequences designed to provide for some addi 
tional property, such as solubility. The amino acid sequences 
of an S. neurona antigen can include sequences in Which one 
or more amino acids have been substituted With another 
amino acid to provide for some additional property, such as to 
remove/ add amino acids capable of disul?de bonding, to 
increase its bio-longevity, alter enzymatic activity, or alter 
interactions, e.g., With gastric acidity. In any case, the peptide 
should posses a bioactive property, such as immunoreactivity, 
immunogenicity, etc. 
The puri?ed polypeptide fragments thus obtained can be 
tested to determine their immunogenicity and speci?city. 
Brie?y, various concentrations of a putative immunogeni 
cally speci?c fragment are prepared and administered to an 
animal and the immunological response (e.g., the production 
of antibodies or cell mediated immunity) of an animal to each 
concentration is determined. The amounts of antigen admin 
istered depend on the subject, e. g. a horse or a guinea pig, the 
condition of the subject, the siZe of the subject, etc. Thereafter 
an animal so inoculated With the antigen can be exposed to the 
parasite to test the potential vaccine effect of the speci?c 
immunogenic fragment. The speci?city of a putative immu 
nogenic fragment can be ascertained by testing sera, other 
?uids or lymphocytes from the inoculated animal for cross 
reactivity With other closely related Sarcocyslis spp. 
A vector comprising the nucleic acids of the present inven 
tion is also provided. The vectors of the invention can be in a 
host capable of expressing the antigenic polypeptide frag 
ments contemplated by the present invention. There are 
numerous E. coli expression vectors knoWn to one of ordinary 
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skill in the art useful for the expression of the antigen. Other 
microbial hosts suitable for use include bacilli, such as Bacil 
lus sublil is, and other enterobacteriaceae, such as Salmonella, 
Serralia, and various Pseudomonas species. In these prokary 
otic hosts one can also make expression vectors, Which Will 
typically contain expression control sequences compatible 
With the host cell (e.g., an origin of replication). In addition, 
any number of a variety of Well-known promoters can be 
present, such as the lactose promoter system, a tryptophan 
(Trp) promoter system, a beta-lactamase promoter system, or 
a promoter system from phage lambda. The promoters Will 
typically control expression, optionally With an operator 
sequence, and have ribosome binding site sequences for 
example, for initiating and completing transcription and 
translation. If necessary, for example, an amino terminal 
methionine can be provided by insertion of a Met codon 5' and 
in-frame With the antigen. Also, the carboxyterminal exten 
sion of the antigenic fragments can be removed using stan 
dard oligonucleotide mutagenesis procedures. 
Additionally, yeast expression can be used. There are sev 
eral advantages to yeast expression systems. First, evidence 
exists that proteins produced in a yeast secretion systems 
exhibit correct disul?de pairing. Second, post-translational 
glycosylation is e?iciently carried out by yeast secretory sys 
tems. In one example, the Saccharomyces cerevisiae pre-pro 
alpha-factor leader region (encoded by the MF.alpha.-l gene) 
is routinely used to direct protein secretion from yeast (Brake 
et al., 1984). The leader region of pre-pro-alpha-factor con 
tains a signal peptide and a pro-segment Which includes a 
recognition sequence for a yeast protease encoded by the 
KEX2 gene: this enZyme cleaves the precursor protein on the 
carboxyl side of a Lys-Arg dipeptide cleavage-signal 
sequence. The antigen coding sequence can be fused in-frame 
to the pre-pro-alpha-factor leader region. This construct is 
then put under the control of a strong transcription promoter, 
such as the alcohol dehydrogenase I promoter or a glycolytic 
promoter. The antigen coding sequence is folloWed by a trans 
lation termination codon Which is folloWed by transcription 
termination signals. Alternatively, the antigen coding 
sequences can be fused to a second protein coding sequence, 
such as Sj26 or .beta.-galactosidase, used to facilitate puri? 
cation of the fusion protein by a?inity chromatography. The 
insertion of protease cleavage sites to separate the compo 
nents of the fusion protein is applicable to constructs used for 
expression in yeast. 
Mammalian cells permit the expression of proteins in an 
environment that favors important post-translational modi? 
cations such as folding and cysteine pairing, addition of com 
plex carbohydrate structures, and secretion of active protein. 
Vectors useful for the expression of antigen in mammalian 
cells are characterized by insertion of the antigen coding 
sequence betWeen a strong viral promoter and a polyadeny 
lation signal. The vectors can contain genes conferring either 
gentamicin or methotrexate resistance for use as selectable 
markers. The antigen and immunoreactive fragment coding 
sequence can be introduced into a Chinese hamster ovary cell 
line using a methotrexate resistance-encoding vector. Pres 
ence of the vector DNA in transformed cells can be con?rmed 
by Southern analysis and production of a cDNA or opposite 
strand RNA corresponding to the antigen coding sequence 
can be con?rmed by northern analysis. A number of other 
suitable host cell lines capable of secreting intact proteins 
have been developed in the art, and include the CHO cell 
lines, HeLa cells, myeloma cell lines, Jurkat cells, etc. 
Expression vectors for these cells can include expression 
control sequences, such as an origin of replication, a pro 
moter, an enhancer, and necessary information processing 
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sites, such as ribosome binding sites, RNA splice sites, poly 
adenylation sites, and transcriptional terminator sequences. 
Preferred expression control sequences are promoters derived 
from immunoglobulin genes, SV40, Adenovirus, Bovine 
Papilloma Virus, etc. The vectors containing the nucleic acid 
segments of interest can be transferred into the host cell by 
Well-knoWn methods, Which vary depending on the type of 
cellular host. For example, calcium chloride transfection is 
commonly utilized for prokaryotic cells, Whereas calcium 
phosphate treatment or electroporation may be used for other 
cellular hosts. 
Alternative vectors for the expression of antigen in mam 
malian cells can be employed, similar to those developed for 
the expression of human gammainterferon, tissue plasmino 
gen activator, clotting Factor VIII, hepatitis B virus surface 
antigen, protease Nexinl, and eosinophil major basic protein. 
Further, the vector can include CMV promoter sequences and 
a polyadenylation signal available for expression of inserted 
nucleic acid in mammalian cells (such as COS7). 
The nucleic acid sequences can be expressed in hosts after 
the sequences have been operably linked to, i.e., positioned to 
ensure the functioning of, an expression control sequence. 
These expression vectors are typically replicable in the host 
organisms either as episomes or as an integral part of the host 
chromosomal DNA. Commonly, expression vectors can con 
tain selection markers, e.g., tetracycline resistance or hygro 
mycin resistance, to permit detection and/ or selection of those 
cells transformed With the desired nucleic acid sequences 
(see, e.g., US. Pat. No. 4,704,362). 
Polynucleotides encoding a variant polypeptide may 
include sequences that facilitate transcription (expression 
sequences) and translation of the coding sequences such that 
the encoded polypeptide product is produced. Construction 
of such polynucleotides is Well knoWn in the art. For example, 
such polynucleotides can include a promoter, a transcription 
termination site (polyadenylation site in eukaryotic expres 
sion hosts), a ribosome binding site, and, optionally, an 
enhancer for use in eukaryotic expression hosts, and, option 
ally, sequences necessary for replication of a vector. 
One presently preferred vector system for expression of the 
peptides of the invention comprises the use of Alphavirus 
vector constructs, for example, as set forth in US. Pat. Nos. 
5,643,576; 5,843,723; 6,156,558; and 6,242,259, the teach 
ings of Which are hereby incorporated herein by reference. 
A puri?ed monoclonal antibody speci?cally reactive With 
S. neurona is also provided. The antibodies can be speci?cally 
reactive With a unique epitope of the antigen or they can also 
react With epitopes of other organisms. The term “reactive” 
means capable of binding or otherWise associating non ran 
domly With an antigen. “Speci?cally reactive” as used herein 
refers to an antibody or other ligand that does not cross react 
substantially With any antigen other than the one speci?ed, in 
this case, S. neurona. Antibodies can be made as described in 
the Examples (see also, HarloW and Lane, Antibodies; A 
Laboratory Manual, Cold Spring Harbor Laboratory, Cold 
Spring Harbor, N.Y., 1988). Brie?y puri?ed antigen can be 
injected into an animal in an amount and in intervals suf?cient 
to elicit an immune response. Antibodies can either be puri 
?ed directly, or spleen cells can be obtained from the animal. 
The cells are then fused With an immortal cell line and 
screened for antibody secretion. The antibodies can be used to 
screen clone libraries for cells secreting the antigen. Those 
positive clones can then be sequenced (see, for example, 
Kelly et al., Bio/Technology, 10: 163-167, (1992) and Beb 
bington et al., Bio/Technology, 10: 169-175, (1992). 
The antibody can be bound to a substrate or labeled With a 
detectable moiety or both bound and labeled. The detectable 
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moieties contemplated by the present invention include, but 
are not limited to ?uorescent, enzymatic and radioactive 
markers. 
A puri?ed S. neurona antigen bound to a substrate and a 
ligand speci?cally reactive With the antigen are also contem 
plated. Such a puri?ed ligand speci?cally reactive With the 
antigen can be an antibody. The antibody can be a monoclonal 
antibody obtained by standard methods and as described 
herein. The monoclonal antibody can be secreted by a hybri 
doma cell line speci?cally produced for that purpose (HarloW 
and Lane, 1988). Likewise, nonhuman polyclonal antibodies 
speci?cally reactive With the antigen are Within the scope of 
the present invention. The polyclonal antibody can also be 
obtained by the standard immunization and puri?cation pro 
tocols (HarloW and Lane, 1988). 
The present invention provides a method of detecting the 
presence of S. neurona in a subject, comprising the steps of 
contacting an antibody-containing sample from the subject 
With a detectable amount of the antigenic polypeptide frag 
ment of the present invention and detecting the reaction of the 
fragment and the antibody, the reaction indicating the pres 
ence of the S. neurona or a previous infection With S. neurona. 
One example of the method of detecting S. neurona is 
performed by contacting a ?uid or tissue sample from the 
subject With an amount of a puri?ed antibody speci?cally 
reactive With the antigen as de?ned herein, and detecting the 
reaction of the ligand With the antigen. It is contemplated that 
the antigen Will be on intact cells containing the antigen, or 
Will be fragments of the antigen. As contemplated herein, the 
antibody includes any ligand Which binds the antigen, for 
example, an intact antibody, a fragment of an antibody or 
another reagent that has reactivity With the antigen. The ?uid 
sample of this method can comprise any body ?uid Which 
Would contain the antigen or a cell containing the antigen, 
such as blood, plasma, serum, cerebrospinal ?uid, saliva, 
feces and urine. Other possible examples of body ?uids 
include sputum, mucus, gastric juice and the like. 
Enzyme immunoassays such as immuno?uorescence 
assays (IFA), enzyme linked immunosorbent assays (ELISA) 
and immunoblotting can be readily adapted to accomplish the 
detection of the antigen. An ELISA method effective for the 
detection of the antigen can, for example, be as folloWs: (1) 
bind the antibody to a substrate; (2) contact the bound anti 
body With a ?uid or tissue sample containing the antigen; (3) 
contact the above With a secondary antibody bound to a 
detectable moiety (e.g., horseradish peroxidase enzyme or 
alkaline phosphatase enzyme); (4) contact the above With the 
substrate for the enzyme; (5) contact the above With a color 
reagent; (6) observe color change. The above method can be 
readily modi?ed to detect antibody as Well as antigen. 
Another immunologic technique that can be useful in the 
detection of S. neurona or previous S. neurona infection uti 
lizes monoclonal antibodies (MAbs) for detection of antibod 
ies speci?cally reactive With S. neurona antigen. Brie?y, sera 
or other body ?uids from the subject is reacted With the 
antigen bound to a substrate (eg an ELISA 96-Well plate). 
Excess sera is thoroughly Washed aWay. A labeled (enzyme 
led, ?uorescent, radioactive, etc.) monoclonal antibody is 
then reacted With the previously reacted antigen serum anti 
body complex. The amount of inhibition of monoclonal anti 
body binding is measured relative to a control (no patient 
serum antibody). The degree of monoclonal antibody inhibi 
tion is a very speci?c test for a particular variety or strain since 
it is based on monoclonal antibody binding speci?city. MAbs 
can also be used for detection directly in cells by IFA. 
A micro-agglutination test can also be used to detect the 
presence of S. neurona in a subject. Brie?y, latex beads (or red 
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blood cells) are coated With the antigen and mixed With a 
sample from the subj ect, such that antibodies in the tissue or 
body ?uids that are speci?cally reactive With the antigen 
crosslink With the antigen, causing agglutination. The agglu 
tinated antigen-antibody complexes form a precipitate, vis 
ible With the naked eye or capable of being detected by a 
spectrophotometer. In a modi?cation of the above test, anti 
bodies speci?cally reactive With the antigen can be bound to 
the beads and antigen in the tissue or body ?uid thereby 
detected. 
In addition, as in a typical sandWich assay, the antibody can 
be bound to a substrate and reacted With the antigen. There 
after, a secondary labeled antibody is bound to epitopes not 
recogniZed by the ?rst antibody and the secondary antibody is 
detected. Since the present invention provides S. neurona 
antigen for the detection of infectious, S. neurona or previous 
S. neurona infection other serological methods such as ?oW 
cytometry and immunoprecipitation can also be used as 
detection methods. 
In the diagnostic methods taught herein, the antigen can be 
bound to a substrate and contacted by a ?uid sample such as 
serum, cerebrospinal ?uid, urine, saliva, feces or gastric juice. 
This sample can be taken directly from the patient or in a 
partially puri?ed form. In this manner, antibodies speci?c for 
the antigen (the primary antibody) Will speci?cally react With 
the bound antigen. Thereafter, a secondary antibody bound to, 
or labeled With, a detectable moiety can be added to enhance 
the detection of the primary antibody. Generally, the second 
ary antibody or other ligand Which is reactive, either speci? 
cally With a different epitope of the antigen or nonspeci?cally 
With, the ligand or reacted antibody, Will be selected for its 
ability to react With multiple sites on the primary antibody. 
Thus, for example, several molecules of the secondary anti 
body can react With each primary antibody, making the pri 
mary antibody more detectable. 
The detectable moiety Will alloW visual detection of a 
precipitate or a color change, visual detection by microscopy, 
or automated detection by spectrometry, radiometric mea 
surement or the like. Examples of detectable moieties include 
?uorescein and rhodamine (for ?uorescence microscopy), 
horseradish peroxidase (for either light or electron micros 
copy and biochemical detection), biotin-streptavidin (for 
light or electron microscopy) and alkaline phosphatase (for 
biochemical detection by color change). The detection meth 
ods and moieties used can be selected, for example, from the 
list above or other suitable examples by the standard criteria 
applied to such selections (HarloW and Lane, 1988). 
The antigen, e.g., a puri?ed antigenic polypeptide frag 
ment encoded by the Sequence Listing of this invention can 
be used in the construction of a vaccine comprising an immu 
nogenic mount of the antigen and a pharmaceutically accept 
able carrier. The vaccine can be the entire antigen, the antigen 
on an intact S. neurona organism, E. coli or other strain, or an 
epitope speci?c to the antigen. The vaccine can also be poten 
tially cross-reactive With antibodies to other antigens. The 
vaccine can then be used in a method of preventing EPM or 
other complications of S. neurona infection. 
Immunogenic amounts of the antigen can be determined 
using standard procedures. Brie?y, various concentrations of 
a putative speci?c immunoreactive epitope are prepared, 
administered to an animal and the immunological response 
(e. g., the production of antibodies) of an animal to each 
concentration is determined. 
The pharmaceutically acceptable carrier can comprise 
saline or other suitable carriers (Arnon, R. (Ed.) Synthetic 
Vaccines I: 83-92, CRC Press, Inc., Boca Raton, Fla., 1987). 
An adjuvant can also be a part of the carrier of the vaccine, in 
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Which case it can be selected by standard criteria based on the 
antigen used, the mode of administration and the subject 
(Arnon, R. (Ed.). 1987). Methods of administration can be by 
oral or sublingual means, or by injection, depending on the 
particular vaccine used and the subject to Whom it is admin 
istered. 
It can be appreciated from the above that the vaccine can be 
used as a prophylactic or a therapeutic modality. Thus, the 
invention provides methods of preventing or treating S. neu 
rona infection and the associated diseases by administering 
the vaccine to a subject. 
Nucleic acid vaccines against S. neurona are also contem 
plated by the invention. The antigenic agent for use in the 
vaccines of the invention can be any nucleic acid, e.g., as set 
forth in the Sequence Listing, that can stimulate an immune 
response against, e.g., SnSAG2, SnSAG3 or SnSAG4 When 
administered to a subject. Suitable nucleic acids include those 
that encode the native proteins of S. neurona, e.g., SnSAG2, 
SnSAG3 or SnSAG4 protein or a variant or antigenic peptide 
fragment thereof, such as, e.g., the nucleic acid set forth in the 
Sequence listing as SEQ ID NO:23, SEQ ID NO:25 or SEQ 
ID NO:27. The nucleic acid used as a vaccine can be e.g., a 
naked DNA, or the nucleic acid can be incorporated in an 
expression vector as set forth herein, e.g., in an Alpha virus 
vector (see, e.g., Rosenberg, S. A., Immunity 101281, 1999). 
The presence of S. neurona can also be determined by 
detecting the presence of a nucleic acid speci?c for S. neurona 
or the antigens of S. neurona encoded by the nucleic acids set 
forth herein. The present invention provides a method of 
detecting the presence of S. neurona in a subject, comprising 
detecting the presence of the nucleic acid encoding an S. 
neurona antigen. As set forth more fully in the examples 
beloW, the speci?city of these sequences for S. neurona can be 
determined by conducting a computerized comparison With 
knoWn sequences, catalogued in GenBank, a computeriZed 
database, using the computer programs Word Search or 
FASTA of the Genetics Computer Group (Madison, Wis.), 
Which search the catalogued nucleotide sequences for simi 
larities to the nucleic acid in question. 
The nucleic acid speci?c for S. neurona antigen can be 
detected utiliZing a nucleic acid ampli?cation technique, such 
as polymerase chain reaction or ligase chain reaction. Alter 
natively, the nucleic acid is detected utiliZing direct hybrid 
iZation or by utiliZing a restriction fragment length polymor 
phism. For example, the present invention provides a method 
of detecting the presence of S. neurona comprising ascertain 
ing the presence of a nucleotide sequence associated With a 
restriction endonuclease cleavage site. In addition, PCR 
primers Which hybridiZe only With nucleic acids speci?c for 
S. neurona can be utiliZed. The presence of ampli?cation 
indicates the presence of S. neurona sequence. In another 
embodiment a restriction fragment of a nucleic acid sample 
can be sequenced directly using, techniques knoWn in the art 
and described herein and compared to the knoWn unique 
sequence to detect S. neurona. In a further embodiment, the 
present invention provides a method of detecting the presence 
of S. neurona by selective ampli?cation by the methods 
described herein. In yet another embodiment S. neurona can 
be detected by directly hybridiZing the unique sequence With 
a S. neurona selective nucleic acid probe. Furthermore, the 
nucleotide sequence could be ampli?ed prior to hybridization 
by the methods described above. 
Altemative probing techniques, such as ligase chain reac 
tion (LCR), involve the use of mismatch probes, i.e., probes 
Which are fully complementary With the target except at the 
point of the mutation. The target sequence is then alloWed to 
hybridiZe both With oligonucleotides Which are fully comple 
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mentary and have oligonucleotides containing a mismatch, 
under conditions Which Will distinguish between the tWo. By 
manipulating the reaction conditions, it is possible to obtain 
hybridization only Where there is fall complementarity. If a 
mismatch is present there is signi?cantly reduced hybridiza 
tion. 
The polymerase chain reaction (PCR) and reverse tran 
scriptase PCR are techniques that amplify speci?c nucleic 
acid sequences With remarkable e?iciency. Repeated cycles 
of denaturation, primer annealing and extension carried out 
With polymerase; e.g., a heat stable enZyme Taq polymerase, 
leads to exponential increases in the concentration of desired 
nucleic acid sequences. Given a knowledge of the nucleotide 
sequence of S. neurona as set forth herein, synthetic oligo 
nucleotides can be prepared Which are complementary to 
sequences Which ?ank the nucleic acid of interest. Each oli 
gonucleotide is complementary to one of the tWo strands. The 
nucleic acid can be denatured at high temperatures (e.g., 
95.degree. C.) and then reannealed in the presence of a large 
molar excess of oligonucleotides. The oligonucleotides, ori 
ented With their 3' ends pointing toWards each other, hybridiZe 
to opposite strands of the target sequence and prime enZy 
matic extension along the nucleic acid template. The end 
product is then denatured again for another cycle. After this 
three-step cycle has been repeated several times, ampli?ca 
tion of a nucleic acid segment by more than one million-fold 
can be achieved. The resulting nucleic acid may then be 
directly sequenced. 
In yet another method, PCR may be folloWed by restriction 
endonuclease digestion With subsequent analysis of the 
resultant products. Nucleotide substitutions can result in the 
gain or loss of speci?c restriction endonuclease sites. The 
gain or loss of a restriction endonuclease recognition site 
facilitates the detection of the organism using restriction frag 
ment length polymorphism (RFLP) analysis or by detection 
of the presence or absence of a polymorphic restriction endo 
nuclease site in a PCR product that spans the sequence of 
interest. 
For RFLP analysis, nucleic acid is obtained, for example 
from the blood, cerebrospinal ?uid, gastric specimen, saliva, 
dental plaque, other bodily ?uids of the subject suspected of 
containing S. neurona, is digested With a restriction endonu 
clease, and subsequently separated on the basis of siZe by 
agarose gel electrophoresis. The Southern blot technique can 
then be used to detect, by hybridization With labeled probes, 
the products of endonuclease digestion. The patterns obtained 
from the Southern blot can then be compared. Using such an 
approach, S. neurona nucleic acid is detected and their mobil 
ity on the gel by determining the number of bands detected 
and comparing this pattern to the nucleic acid from S. neu 
rona. 
Similar creation of additional restriction sites by nucle 
otide substitutions at the disclosed mutation sites can be 
readily calculated by reference to the genetic code and a list of 
nucleotide sequences recogniZed by restriction endonu 
cleases. Single strand conformational analysis (SSCA) offers 
a relatively quick method of detecting sequence changes 
Which may be appropriate in at least some instances. 
In general, primers for PCR and LCR are usually about 20 
bp in length and the preferable range is from 15-25 bp. Better 
ampli?cation is obtained When both primers are the same 
length and With roughly the same nucleotide composition. 
Denaturation of strands usually takes place at about 
94.degree. C. and extension from the primers is usually at 
about 72.degree. C. The annealing temperature varies accord 
ing to the sequence under investigation. Examples of reaction 
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times are: 20 mins denaturing; 35 cycles of 2 min, 1 min, 1 
min for annealing, extension and denaturation; and ?nally a 5 
min extension step. 
PCR ampli?cation of speci?c alleles (PASA) is a rapid 
method of detecting single-base mutations or polymor 
phisms. PASA (also knoWn as allele speci?c ampli?cation) 
involves ampli?cation With tWo oligonucleotide primers such 
that one is allele-speci?c. The desired allele is ef?ciently 
ampli?ed, While the other allele(s) is poorly ampli?ed 
because it mismatches With a base at or near the 3' end of the 
allele-speci?c primer. Thus, PASA or the related method of 
PAMSA may be used to speci?cally amplify the mutation 
sequences of the invention. Where such ampli?cation is done 
on S. neurona isolates or samples obtained from an indi 
vidual, it can serve as a method of detecting the presence of S. 
neurona. As mentioned above, a method knoWn as ligase 
chain reaction (LCR) can be used to successfully detect a 
single-base substitution. LCR probes may be combined or 
multiplexed for simultaneously screening for multiple differ 
ent mutations. Thus, LCR can be particularly useful Where, as 
here, multiple mutations are predictive of the same disease. 
The present invention is more particularly described in the 
folloWing examples Which are intended as illustrative only, 
since numerous modi?cations and variations therein Will be 
apparent to those skilled in the art. 
EXAMPLES 
Identi?cation and CharacteriZation of SnSAGl 
Surface biotinylation of extracellular meroZoites revealed 
only tWo dominant labeled molecules that migrate at about 30 
kDa and 16 kDa in SDS-PAGE. Analysis of a S. neurona EST 
database (currently 1800+ sequences) identi?ed an ortho 
logue of the 31-kDa surface antigen from Sarcocyslis muris. 
The sequence of the S. neurona surface antigen gene, desig 
nated SnSAGl, is predicted to encode a 276-residue protein 
With an amino-terminal signal peptide and a carboxy-termi 
nal GPI anchor addition. Antiserum raised against recombi 
nant SnSAGl recogniZed a 25-kDa antigen in Western blots 
of non-reduced S. neurona lysates, consistent With the 
molecular Weight predicted for the mature SnSAGl. Under 
reducing conditions, SnSAGl migrated aberrantly at about 
30 kDa, similar to What has been observed in Western blot 
analyses of reduced T gondii surface antigens. lmmuno?uo 
rescence labeling of SnSAGl during intracellular groWth of 
S. neurona indicated that the protein is expressed throughout 
schiZogony. Interestingly, a ?lamentous staining pattern Was 
observed in intermediate schiZonts that likely re?ects local 
iZation of the surface antigen to previously-described invagi 
nations of the schiZont surface membrane. 
Parasite Culture 
S. neurona strain SN3 [Granstrom, 1992 #1600] meroZoi 
tes Were propagated by serial passage in bovine turbinate 
(BT) cells and maintained in RPMI 1640 medium supple 
mented With 10% fetal bovine serum, 2 mM sodium pyruvate, 
Pen/ Strep FungiZone (BioWittaker, lnc .). Extracellular mero 
Zoites Were harvested and puri?ed from disrupted host cell 
monolayers by ?ltration through 3.0 pm membranes, as 
described previously for Neospora caninium [HoWe, 1997 
#1372]. 
lmmunoscreen of S. neurona cDNA Library 
Construction and analyses of the cSn.1 S. neurona mero 
Zoite cDNA library has been described previously [HoWe, 
2001 #1787]. The library Was plaqued for 3 hrs at 420 C. on 
XLl -Blue MRF' E. coli host cells (Stratagene) groWn on 150 
US 7,524,946 B2 
17 
mm NZY agar plates. When plaques became visible, plates 
Were overlayed With nitrocellulose ?lters previously soaked 
in 10 mM isopropyl-[3-D-thiogalactopyranoside (IPTG) for 
an additional 3 hr incubation at 370 C. Filters Were lifted from 
the plates, Washed With TNT buffer (10 mM Tris-HCl, pH 7 .5, 
150 mM NaCl, 0.05% TWeen 20), and blocked in phosphate 
buffered saline (PBS), 5% dry milk, 5% normal goat serum, 
0.05% TWeen 20. 
Antigenic cDNA clones Were identi?ed by screening With 
cerebrospinal ?uid (CSF) from a horse that had been naturally 
infected With S. neurona and exhibited a high titer of intrath 
ecal antibodies against S. neurona in Western blot analysis. 
Prior to screening the S. neurona cDNA library, the CSF Was 
diluted 1:20 in PBS, 0.1% dry milk, 0.1% normal goat serum, 
0.05% TWeen 20 and incubated for 30 min With ?lters carry 
ing plaque lifts of a previously-described N. caninum cDNA 
library [HoWe, 1999 #1759] to remove antibodies that Were 
reactive With E. coli and phage proteins. After adsorption of 
potential cross-reactive antibodies, the diluted CSF solution 
Was incubated for 1 hr With the cSn.1 ?lters. After Washing, 
?lters Were incubated for 1 hr With goat anti-equine IgG 
conjugated to horseradish peroxidase (HRP) (Jackson Immu 
noresearch Labs, Inc.) diluted to 110,000. Immuno-reactive 
phage plaques Were picked With sterile pipet tips and sus 
pended in 40 pl of SM buffer (50 mM Tris-HCl, pH 7.5, 100 
mM NaCl, 8 mM MgSO4, 0.01% gelatin). The cDNA inserts 
Were PCR ampli?ed using the T3 and T7 oligonucleotide 
primers, and the resulting products Were analyZed by agarose 
gel electrophoresis. Sequencing reactions using T3 primer 
Were conducted on the ampli?ed cDNAs to provide a prelimi 
nary identi?cation of the immunoreactive clones. Phagemid 
excision Was performed on selected cDNA clones, and plas 
mids Were rescued in SOLR cells according to the manufac 
turer’s protocol (Stratagene). 
S. neurona EST Database Searches and Sequence Analyses 
S. neurona homologues to previously-characterized coc 
cidian surface antigens Were identi?ed in the S. neurona 
clustered EST database (See, e.g., paradb.cis.upenn.edu/ 
sarco/index.html) using the BLAST (basic local alignment 
search tool) set of programs [Altschul, 1990 #616]. At the 
time the database Was searched, it contained 686 consensus 
sequences that had been generated from 1883 S. neurona 
ESTs. Selected cDNAs Were obtained from the archived col 
lection of EST clones and sequenced using ABI Prism Big 
Dye Terminator Cycle Sequencing reaction mix (Perkin 
Elmer Applied Biosystems). The reactions Were puri?ed 
using Centri-Sep spin columns (Princeton Separations), and 
the eluted extension products Were resolved and analyZed on 
an ABI 310 Genetic AnalyZer. Sequence analyses Were con 
ducted With Genetics Computer Group (GCG) softWare [De 
vereux, 1984 #1 176] and programs available on the National 
Center for Biotechnology Information (N CBI) Web site (See, 
e.g., WWW.ncbi.nlm.nih.gov/) and the Expert Protein Analy 
sis System (ExPASy) server of the SWiss Institute of Bioin 
formatics (See, e.g., WWW.expasy.ch/). Multiple sequence 
alignments Were performed using Multalin softWare [Corpet, 
1988 #2046]. The sequence reported herein has been depos 
ited into GenBank under accession number AY032845. 
Recombinant SnSAG1 Expression and Generation of Poly 
clonal Antiserum 
The SnSAG1 open reading frame Without the predicted 
amino-terminal signal peptide and the carboxyl-terminal 
hydrophobic tail Was ampli?ed by PCR from the pSnAg8 
cDNA using primers that introduce a NdeI restriction site 
prior to base 45 (numbered from the initiation codon) and an 
XhoI site after base 743. The ampli?cation product Was 
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digested With NdeI and XhoI, ligated into NdeI/XhoI-di 
gested pET22b expression vector (Novagen), and trans 
formed into INVotF' E. coli. The resulting expression plas 
mid, designated prSnSAG1, Was transformed into BL21 
CodonPlus E. coli (Stratagene), and a clone that expressed 
high levels of recombinant SnSAG1 (rSnSAGl) Was selected 
for use. The histidine-tagged rSnSAG1 Was puri?ed by 
nickel-column chromatography according to the manufactur 
er’s protocol (N ovagen), and monospeci?c polyclonal antis 
era Were produced against the puri?ed protein by immuniza 
tion of a rabbit and rat (Cocalico Biologicals, Inc.). 
Western Blot Analysis 
Parasites Were lysed in sodium dodecyl sulfate (SDS) 
sample buffer supplemented With protease inhibitor cocktail 
(Sigma) and 2% 2-mercaptoethanol, and the lysates Were 
separated in 10% or 12% polyacrylamide gels [Laemmli, 
1970 #393]. Proteins Were transferred to nitrocellulose mem 
branes by semidry electrophoretic transfer in Tris-glycine 
buffer (pH 8.3). Membranes Were blocked With PBS contain 
ing 5% nonfat dry milk, 5% goat serum, and 0.05% TWeen 20, 
and then incubated for 1 hr With primary antibody. After 
Washing, membranes Were incubated With HRP-conjugated 
immunoglobulin G secondary antibody (Jackson Immunore 
search Labs, Inc.). Blots Were Washed, processed for chemi 
luminescence using Supersignal substrate (Pierce Chemical 
Company), and exposed to ?lm. 
Biotinylation of Surface Proteins and Precipitation With 
Immobilized Streptavidin 
Approximately 3><107 freshly harvested meroZoites Were 
resuspended in 1 ml cold PBS (pH 7.8). Sulfo-N-hydroxy 
succinimide-biotin (Pierce) Was added to a concentration of 
0.5 mg/ml and incubated at room temperature for 30 min. The 
labeled parasites Were Washed tWice With 5 ml of PBS and 
stored at —200 C. 
The labeled parasite pellet Was lysed With 1 ml radio 
immunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 
7.5], 1% Triton X-100, 0.5% sodium deoxycholate, 0.2% 
SDS, 100 mM NaCl, 5 mM EDTA) supplemented With 
RNase, DNase, protease inhibitor cocktail, and the sample 
Was centrifuged at 16,000><g to remove the insoluble fraction. 
The soluble proteins Were incubated With UltraLink immo 
biliZed streptavidin (Pierce), and the precipitated biotin-la 
beled protein fraction Was analyZed by Western blotting, as 
described above. 
Immuno?uorescent Labeling of Extracellular and Intracellu 
lar Parasites 
For detection of SnSAG1 on extracellular parasites and in 
trails deposited by gliding parasites, freshly lysed meroZoites 
Were suspended in fresh RPMI 1640 and incubated on poly 
L-lysine-coated slides for approximately 30 min. Slides Were 
Washed With PBS, and the parasites Were ?xed in 2.5% for 
malin-PBS containing 0.01% glutaraldehyde. For detection 
of SnSAG1 on intracellularparasites, meroZoites Were inocu 
lated onto BT cells groWn on LabTek chamber slides (Nuc). 
At 24 hr, 48 hr, or 72 hr post-inoculation, the cells Were ?xed 
in 2.5% formalin-PBS/0.01% glutaraldehyde and permeabi 
liZed With 0.2% TritonX-100. After incubation With primary 
antibody, the slides Were rinsed, then incubated With ?uores 
cein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG 
(Jackson Immunoresearch Labs, Inc.). The slides Were 
mounted in Vectashield With DAPJ (Vector Laboratories, 
Inc.) and examined With a Zeiss axioscope equipped for epi 
?uorescence microscopy. 
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Results 
Isolation and Analysis of Immunoreactive cDNA Clones 
A primary screen of the cSn.1 cDNA library identi?ed 
multiple immunoreactive phage plaques, and a total of 25 
plaques Were isolated and resuspended in SM buffer. Ampli 
?cation of the cDNA inserts With T3 and T7 oligonucleotides 
revealed that 22 of the phage clones had similar lengths of 
approximately 1500 base pairs (bp), and sequence analysis 
using T3 primer indicated that these 22 cDNAs represent the 
same gene. A secondary screen Was performed on ?ve of the 
selected cDNAs, and tWo highly reactive phage clones, des 
ignated SnAgI.8 and SnAgI.9, Were chosen for further analy 
ses. 
To obtain a preliminary identi?cation of the parasite pro 
tein encoded by the selected cDNAs, the SnAgI.9 clone Was 
used to a?inity purify antibodies that bind the antigen 
expressed by this clone, and the eluted antibodies Were used 
to probe a Western blot of S. neurona meroZoite lysate. As 
shoWn in FIG. 1, the puri?ed antibodies reacted With an 
approximately 31-kDa antigen in reduced S. neurona lysate. 
Furthermore, the antigen revealed by the phage-puri?ed anti 
bodies comigrated With a protein that is recogniZed by equine 
or rabbit antisera against S. neurona as the major immun 
odominant antigen of this parasite (FIG. 1, lanes 2 and 3). 
This result implies that the 22 matching cDNA clones isolated 
during the library screen and represented by SnAgI.8 and 
SnAgI.9 encode the immunodominant antigen of S. neurona. 
Full-length sequence analysis of SnAgI.8 revealed a cDNA 
insert of 1493 nucleotides, With an open reading frame (ORF) 
that encodes a 276 amino acid protein. Sequence analysis of 
SnAgI.9 indicated that this clone Was virtually identical to 
SnAgI.8, although its 3' untranslated region (UTR) Was 
approximately 160 nucleotides longer due to an alternative 
polyadenylation site. A hydrophobicity plot of the encoded 
protein shoWed hydrophobic domains at both termini, Which 
correspond to a predicted signal peptide at the amino termi 
nus and a GPI anchor addition sequence at the carboxyl 
terminus (data not shoWn). The signal peptide cleavage is 
predicted to occur at Alals-Argl6 (SignalP; [Nielsen, 1997 
#2047], and the most likely GPI transamidase cleavage site is 
predicted to be at Ala247-Asn248 (DGPI; SWiss Institute of 
Bioinformatics). A single N-glycosylation site Was predicted 
at residues 140-143. Removal of the N-terminal and C-termi 
nal signal sequences results in a mature protein of 242 amino 
acids that has a predicted molecular Weight of 24.2 kDa 
before any potential post-translational modi?cations (e.g., 
glycolipid anchor addition, glycosylation). 
To identify homology to previously characteriZed 
sequences, BLAST searches [Altschul, 1990 #616] of the 
non-redundant GenBank databases Were conducted With the 
SnAgI.8 coding sequence as the query. These searches 
revealed a statistically signi?cant similarity to the 31 kDa 
major surface antigen of Sarcocyslis muris [Eschenbacher, 
1992 #1767] and a less signi?cant but recogniZable similarity 
to several SAG2-related surface antigens from T gondii [Le 
kutis, 2000 #2049] . (FIG. 2). In conjunction With the Western 
blot analysis and the predictions of a signal peptide and a 
GPI-anchor addition, these results suggested that the gene 
represented by the SnAgI.8 and SnAgI.9 cDNAs encodes an 
immunodominant surface antigen of S. neurona; conse 
quently, We tentatively designated this protein SnSAGl, fol 
loWing the genetic nomenclature that is utiliZed for the related 
apicomplexan parasites T gondii and N. caninum [Sibley, 
1991 #13; HoWe, 1999 #1759]. 
The sequence analysis for SnSAG2, SnSAG3, and 
SnSAG4 as Well as for the SnGF Cluster sequences provided 
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by the invention and set forth herein have been derived in a 
fashion similar to that set forth above for SnSAGl. These 
novel nucleotide sequences and protein sequences of Sarco 
cyslis neurona can be utiliZed in the production of vaccines 
and/or antigen/ antibody kits for prevention and diagnosis of 
Sarcocyslis neurona infection. One preferred embodiment of 
the invention is a vaccine comprised of an alpha virus expres 
sion vector and nucleic acid selected from the nucleic acid 
sequences disclosed herein. 
Identi?cation of S. neurona Surface Antigens and Expression 
as Recombinant Proteins 
Analysis of the S. neurona EST database revealed four 
paralogous proteins that are homologous to the SAG and SRS 
surface antigens of Toxoplasma gondii. Each S. neurona gene 
Was predicted to encode a protein that possessed an amino 
terrninal signal peptide and a carboxyl-terminal glycolipid 
anchor site, consistent With the proteins being surface anti 
gens. Because of their similarity to Toxoplasma SAGs and 
their probable surface display on meroZoites, the four S. neu 
rona proteins Were designated SnSAGl, SnSAG2, SnSAG3, 
and SnSAG4. The four putative surface antigens Were each 
expressed as a recombinant protein in E. coli, and these Were 
used to immuniZe rabbits and rats for monospeci?c poly 
clonal antisera production. The resulting polyclonal antisera 
Were used in Western blot analysis of reduced (With 2-mer 
captoethanol) S. neurona lysate to reveal each of the SnSAGs 
(See, FIG. 3). The mature forms of native SnSAGl and 
SnSAG4 are predicted to be approximately 24 kDa, but these 
antigens co-migrated at approximately 30-32 kDa and corre 
spond to the immunodominant antigen Sn30 that has been 
described previously (See, FIG. 3) (Granstrom et al., 1993; 
Liang et al., 1998). SnSAGl has also been identi?ed by others 
as a major surface antigen matching the immunodominant 
Sn30 band (Ellison et al., 2002), but it is apparent that 
SnSAG4 likely contributes to the antibody reactivity at this 
molecular Weight. The mature form of SnSAG2 is predicted 
to be about 12 kDa, but this antigen migrated at approxi 
mately 18-19 kDa and corresponds to the previously 
described immunodominant Sn16 antigen (See, FIG. 3) 
(Granstrom et al., 1993; Liang et al., 1998). Mature SnSAG3 
is predicted to be 23 kDa, but migrated at about 28 kDa (See, 
FIG. 3). The aberrant migration of the SnSAGs under reduc 
ing conditions is a characteristic that has been observed pre 
viously for the surface antigens of both T gondii (Burg et al., 
1988; Cesbron-DelauW et al., 1994) andN. caninum (HoWe et 
al., 1998). Importantly, the Western blot experiments demon 
strated that the recombinant forms of the SnSAGs are recog 
niZed by antibodies from S. neurona-infected horses. There is 
strong concordance betWeen antibody recognition of recom 
binant SnSAGl (rSnSAGl) and standard Western blot analy 
sis of complete parasite antigen (i.e., S. neurona meroZoite 
lysate). Similar results Were obtained With rSnSAG2, rSn 
SAG3, and rSnSAG4. These data demonstrate the utility of 
using the rSnSAGs in ELISA formats to monitor antibody 
responses in S. neurona-infected horses. 
Enzyme-Linked Immunosorbent Assays (ELISAs) Based on 
Recombinant S. neurona Surface Antigens (rSnSAGs) 
The rSnSAGs expressed in E. coli have been shoWn in 
Western blots to be recogniZed by equine antibodies; conse 
quently, these recombinant antigens can be utiliZed as the key 
reagents for developing ELISAs based on single S. neurona 
antigens. An ELISA test Was developed for each of the four 
rSnSAGs that have been identi?ed by the invention. 
Expression and Puri?cation of Recombinant SnSAGs. 
To produce highly puri?ed recombinant forms of the 
SnSAGs, the genes for each antigen Were cloned into the 
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pET22b expression plasmid from Novagen (Madison, Wis). 
This plasmid vector provides a carboxyl-terminal fusion to a 
6-residue oligohistidine domain (His-Tag), Which binds to 
metal ion a?inity columns and alloWs for the ef?cient one 
step puri?cation of the expressed recombinant protein. Plas 
mid constructs Were transformed into BL21 DE3) host cells 
(CodonPlus, Stratagene, lnc .), and expression of recombinant 
protein Was induced by addition of IPTG. Bacterial clones 
that reliably expressed the recombinant SnSAGs Were 
selected and cyropreserved for future study. The recombinant 
S. neurona surface antigens have been designated rSnSAGl, 
rSnSAG2, rSnSAG3, and rSnSAG4. 
To obtain recombinant protein, the appropriate bacterial 
clone Was grown to logarithmic phase in LB medium, and 
protein expression Was induced by addition of IPTG to the 
culture. The recombinant protein Was extracted from inclu 
sion bodies With 6 M urea and puri?ed from the host cell 
lysate by Ni++-column chromatography according to the 
manufacturer’s protocol (His-Bind resin and buffers, 
Novagen). Urea Was removed by dialysis. If necessary, 
recombinant proteins Was concentrated by centrifugal ultra 
?ltration in Centricon-10 columns (Amicon). 
ELISA Assay 
The SN3 strain of S. neurona and the Oregon strain of 
Neospora hughesi Were maintained by serial passage in 
bovine turbinate cell monolayers. Upon lysis of the host cell 
monolayer, Zoites Were dispersed and ?ltered (3 .0 pm Nucle 
opore membrane ?lter, Whatman) to remove debris. Har 
vested parasites Were counted, Washed, and stored at —200 C. 
Concentration of puri?ed recombinant proteins prepared 
as described above Was determined by a calorimetric assay 
(Coomassie Plus Protein Assay Reagent, Pierce). Puri?ed 
rSnSAGl, rSnSAG2, rSnSAG3, and rSnSAG4 Were diluted 
in buffer (0.5 M NaCl and 20 mM Tris-HCl) Without urea to 
?nal protein concentrations of 8.15 pg/ml, 23.0 pg/ml, 14.56 
pg/ml, and 10.3 pg/ml, respectively. 
Positive control serum samples Were obtained from tWo 
horses With histologically con?rmed EPM. The negative con 
trol sample for all assays Was a preinfection serum sample 
from a Weanling used in an experimental infection trial. 
Thirty six equine serum samples submitted for S. neurona 
serology testing Were used for standardization of the rSnSAG 
ELlSAs. The samples had previously been classi?ed as posi 
tive or negative by Western blot. TWenty-seven samples from 
horses of con?rmed EPM status Were obtained from a collec 
tion of the University of Kentucky Gluck Equine Research 
Center. All cases Were con?rmed by histological examination 
of central nervous system tissues for the presence of lesions 
consistent With EPM, as Well as Western blot analysis of CSF 
?uids. Three equine serum samples from an S. fayeri chal 
lenge trial Were used to examine assay cross-reactivity. An N. 
hughesi positive control serum sample Was also evaluated. 
Native and recombinant proteins Were suspended in SD 
S-PAGE buffer supplemented With protease inhibitor cocktail 
(Sigma) and separated on 12% polyacrylamide gels. For 
Western blot proteins Were transferred to nitrocellulose mem 
branes by semi-dry electrophoresis. Membranes Were 
blocked With PBS containing nonfat dry milk, 0.1% TWeen 
20, and 5% normal goat serum, and incubated for 1 hour in 
primary antibody solution. The membranes Were Washed, 
folloWed by incubation for 45 min. With horseradish peroxi 
dase-conjugated secondary antibodies (Jackson lmmunoRe 
search Laboratories, Inc.). Membranes Were processed for 
chemiluminescent detection using SuperSignal substrate 
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(Pierce) and exposed to radiographic ?lm or documented 
With a FluorChem 8800 imaging system (Alpha lnnotech 
Corp.). 
For rSnSAS ELlSAs, high-binding 96-Well plates (Com 
ing) Were incubated overnight at 40 C. With 100 pl puri?ed 
rSnSAGl, rSnSAG2, rSnSAG3, or rSnSAG4 diluted to 0.20 
pg/ml, 1.00 pg/ml, 0.09 pg/ml, and 0.21 pg/ml, respectively. 
The plates Were rinsed With PBS/0.05% TWeen 20 and 
blocked for 1.5 h at room temperature With PBS/ 1% TWeen 
20/ 0.5% normal goat serum/ 0.001 g/ml nonfat dry milk. Pri 
mary sera or CSF Was diluted With PBS/ 1% TWeen 20/0.5% 
normal goat serum/0.001 g/ml nonfat dry milk. One hundred 
pl aliquots of the sera or CSF containing mixed antibody 
populations Were added to duplicate Wells and incubated for 
2 h at room temperature. The Wells Were rinsed, and then 
incubated for 2 h at room temperature With 150 pl of horse 
radish peroxidase-conjugated goat anti-horse immunoglobu 
lin G (IgG) secondary antibody (Jackson lmmunoResearch 
Laboratories, Inc.) diluted to 1:10,000 in PBS/ 1% TWeen 
20/0.5% normal goat serum/0.001 g/ml nonfat dry milk. The 
Wells Were then again rinsed. The chromogenic substrate 
o-phenylenediamine dihydrochloride (Sigma) at 0.4 mg/ml 
(200 pl) Was added. After 10 min incubation, the reaction Was 
stopped With 50 pl of 3 M H2SO4, and OD490 Was measured 
in an Emax microplate reader (Molecular Devices). To account 
for interplate variation, the OD of each sample Was expressed 
as a percentage of the high positive standard on the plate. 
Serum antibody titers against rSnSAG4 Were detected in 
25 of 26 (96.2%) EPM-con?rmed horses (see FIG. 6). The 
rSnSAG2 and rSnSAG3 ELlSAs yielded seropositive results 
in 24 of26 (92.3%) EPM-con?rmed horses. Only 18 ofthe 26 
(69.2%) horses had detectable serum antibody titers against 
rSnSAGl. In total, 18 (81.8%), 18 (81.8%), 20 (90.0%), and 
21 (95.5%) of the 22 CSF samples had detectable antibody 
titers against rSnSAGl, rSnSAG2, rSnSAG3, and rSnSAG4, 
respectively (see FIG. 7). No signi?cant cross-reactivity of 
the ELlSAs Was found When tested against samples contain 
ing antibodies to tWo related pathogens, S. fayeri and S. 
hughesi (data not shoWn). 
Expression of Recombinant S. neurona Surface Antigens 
(rSnSAGs) in Mammalian Cells 
The open reading frame of each SnSAG as previously 
described Was directionally cloned into the Kpnl and Xbal 
restriction sites of the pVAXl DNA vaccine plasmid vector 
(lnvitrogen), and the ?delity of the pVAXzSnSAG plasmid 
constructs Was con?rmed by expression in COS-1 (green 
monkey kidney) cells With (+GPl) and Without (—GPI) the 
GPI anchor. Cells Were groWn on coverslips in 24-Well plates. 
The pVAX: SnSAG plasmids Were transfected into the COS-1 
cells using the cationic lipid reagent Lipofectamine 2000 
(lnvitrogen). At 48 hr post-transfection, the coverslips Were 
removed and the cells Were ?xed With formalin. The cells 
Were then labeled With an anti-rabbit SnSAG serum as appro 
priate, folloWed by goat anti-rabbit antibody conjugated to 
?uorescein isothiocyanate (FITC). Cell nuclei Were labeled 
With DAPI for contrast. As shoWn in FIG. 8, mammalian cells 
clearly expressed each transfected surface antigen (SnSAGl, 
SnSAG2, SnSAG3, and SnSAG4). 
Accordingly, a simple, reliable assay is provided for detec 
tion of S. neurona infection. lmportantly, the assays did not 
cross-react With antisera against related pathogens. The assay 
described herein provides numerous advantages over current 
serologic assays, including ease of use, high sample through 
put, and more objective interpretation of results. Further, the 
use of recombinant S. neurona surface antigens obviates the 
need to propagate parasites in tissue culture. Relative to 























